TEVA · Teva Pharmaceutical Industries Ltd · Metrics
Market Cap
$42.94B
Shares
1.17B
TEVA metrics
77 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$36.85
Market cap
$42.94B
Price action
20 metricsPrice change (1W)
+1.6%
Price change (30D)
+1.7%
Price change (3M)
+6.7%
Price change (6M)
+16.6%
Price change (YTD)
+17.8%
Price change (1Y)
+90.5%
Trailing year
Price change (5Y)
+291.9%
52-week high
$38.10
52-week low
$18.34
Change from 52-week high
-3.5%
Change from 52-week low
+100.4%
Annualized volatility
39.8%
Annualized volatility (3M)
37.3%
Beta
0.7
RSI (14D)
54.3
Price vs SMA 50
+6.0%
Price vs SMA 200
+12.6%
Avg volume (3M)
5.52M
Relative volume
0.8
Average dollar volume
$190.30M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
1.17B
Valuation
12 metricsP / E (TTM)
60.3
Trailing earnings · reciprocal yield 1.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.0×
reciprocal yield 33.3%
P / book
5.5
reciprocal yield 18.3%
FCF yield
3.2%
TTM · current market cap
Buyback yield
0.0%
P / FCF
31.4
reciprocal yield 3.2%
P / operating cash flow
22.3
reciprocal yield 4.5%
Earnings yield
1.7%
Historical valuation
8 metricsP / E historical average (3Y)
38.6×
reciprocal yield 2.6%
P / E historical average (5Y)
31.9×
reciprocal yield 3.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-07-29
Profitability
9 metricsGross margin
64.4%
Operating margin
11.4%
Trailing 12 months
Net margin
5.0%
Gross profit (TTM)
$9.08B
Operating profit (TTM)
$1.60B
Net income (TTM)
$707.00M
Trailing 12 months
Diluted EPS (TTM)
$0.61
FCF margin
9.6%
Effective tax rate
1.7%
Growth
11 metricsRevenue growth YoY
-0.8%
Year over year
Net income growth YoY
-304.3%
Revenue (TTM)
$14.10B
Trailing 12 months
EPS growth YoY
-304.2%
Shares change YoY
+0.3%
Year over year · more shares
Revenue CAGR (3Y)
+5.0%
Revenue CAGR (5Y)
+0.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+3.3%
FCF CAGR (5Y)
+12.5%
Quality
14 metricsReturn on equity
9.1%
Return on assets
1.8%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
$2.59B
Free cash flow (TTM)
$1.35B
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.65B
Total assets
$39.86B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$1.90B
Capital expenditures (TTM)
$550.00M
R&D (TTM)
$1.71B
SG&A (TTM)
—
Stock compensation (TTM)
$168.00M
R&D / revenue
12.2%
Stock compensation / revenue
1.2%
Ownership (13F)
3 metrics13F filers
681
13F filer change QoQ
+21
Institutional ownership
65.4%
Short interest
3 metricsShort interest
3.1%
Latest settlement · 6.6 days to cover
Days to cover
6.6d
Short-squeeze score
57 / 100
Insider activity
2 metricsNet insider buying (90D)
−$2.71M
Insider-sentiment score
35 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
818686
CUSIP
881624209
13F (30d)
322 filings
321 filers
Visit website
Investor relations